COVID-19 is forcing everyone to reconsider how they work. At Symcel, while we place a lot of value on personal interactions, we also have strong digital workflows that allow us to do our jobs remotely. These workflows have prepared us for the...
The first publication from Symcel’s European H2020 project was published at the end of January. The project named BADGER (Bacterial Analysis and Diagnostics through Growth and Energy-release in Real-time) focuses on clinical validation for new...
The Bjarnsholt lab at the Costerton Biofilm Center finalized the purchase of a calScreener™ as part of a Novo Nordisk Fonden Tandem grant to study atopic dermatitis.
Symcel’s CEO & CSO during their visit at Professor Müller’s lab. Internationally leading group at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) has acquired a calScreener to be used in their screening of novel antimicrobials. ...
Our Production and Application Engineer, Sandra Månsson, with the first calScreener she built.
Why is antibiotic resistance a global threat? The challenges of antibiotic resistance, the current situation that marks it as a WHO priority and the potential of customized therapy are some of the issues that the CEO of Symcel, Dr Jesper Ericsson,...
Our colleague Dr. Karin Gillner recently had a feature article on brown fat treatment research published in Journal for Clinical Studies.
Symcel appoints two new board members to bolster R&D business growth and expansion into the clinical diagnostics market
L-R: Dr Marta Veses Garcia, Pelle Friberg and Dr Karin Gillner Symcel – producers of the cell-based assay tool for real-time cell metabolism measurements, calScreener — is expanding to bring its patented technology to the clinical antimicrobial...
Symcel secures €3.6 million Horizon 2020 Phase II grant for clinical validation of customized antimicrobial susceptibility testing. Multi-resistant bacterial sepsis infections to be validated utilising Symcel’s sensitive screening technology Symcel:...